KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Ratio (2016 - 2025)

Rigel Pharmaceuticals has reported Equity Ratio over the past 16 years, most recently at 0.76 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.76 for Q4 2025, up 3701.35% from a year ago — trailing twelve months through Dec 2025 was 0.76 (up 3701.35% YoY), and the annual figure for FY2025 was 0.76, up 3701.35%.
  • Equity Ratio for Q4 2025 was 0.76 at Rigel Pharmaceuticals, up from 0.48 in the prior quarter.
  • Over the last five years, Equity Ratio for RIGL hit a ceiling of 0.76 in Q4 2025 and a floor of 0.28 in Q3 2023.
  • Median Equity Ratio over the past 5 years was 0.0 (2022), compared with a mean of 0.06.
  • Biggest five-year swings in Equity Ratio: crashed 735.86% in 2023 and later surged 3701.35% in 2025.
  • Rigel Pharmaceuticals' Equity Ratio stood at 0.18 in 2021, then tumbled by 155.86% to 0.1 in 2022, then crashed by 140.97% to 0.24 in 2023, then surged by 108.21% to 0.02 in 2024, then surged by 3701.35% to 0.76 in 2025.
  • The last three reported values for Equity Ratio were 0.76 (Q4 2025), 0.48 (Q3 2025), and 0.4 (Q2 2025) per Business Quant data.